•  
     
     
    Type Size
     

    Osteoprotection by semaphorin 3A

    The authors show that semaphorin 3A (Sema3A) both suppresses osteoclastic bone resorption and increases osteoblastic bone formation. The binding of Sema3A to neuropilin-1 (Nrp1) inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation by inhibiting the immunoreceptor tyrosine-based activation motif (ITAM) and RhoA signalling pathways. These results imply that semaphorin 3A has potential as a therapeutic agent for metabolic bone diseases.

    http://www.nature.com/nature/journal/v485/n7396/full/nature11000.html

    Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details